Commonly Used Lab CPT codes by Pathology coders

Lab CPT codes are used very frequently by medical coders. For any test or screening, lab procedures are order and then the respective procedure code is reported for payment. I have also worked for a little time in pathology facility, and I used most of the lab procedure codes. So, let use checkout today the most common lab CPT codes in medical coding.

Read also: Coding tips for hydration CPT codes 

CPT code 36415-36416


In this procedure a needle is inserted into the skin over a vein to puncture the blood vessel and withdraw blood for venous collection. For such procedure procedures CPT code 36415 is reported. For procedure code 36416, a prick is made into the finger, heel, or ear and capillary blood that pools at the puncture site is collected in a pipette. For both cases, the blood is used for diagnostic study and no catheter is placed.

Do not use modifier 63 in conjunction with 36415.

CPT code 36410, venipuncture necessitating physician's skill, is defined as a venipuncture for which the skill of a physician is required for diagnostic or therapeutic purposes.

Commonly Used Lab CPT codes by Pathology coders

USe of CPT 80053 


This procedure codes comprises of different test. Hence it is named as Comprehensive Metabolic Panel. This panel includes the following tests: albumin (82040), total bilirubin (82247), total calcium (82310), carbon dioxide (bicarbonate) (82374), chloride (82435), creatinine (82565), glucose (82947), alkaline phosphatase (84075), potassium (84132), total protein (84155), sodium (84295), alanine amino transferase (ALT) (SGPT) (84460), aspartate amino transferase (AST) (SGOT) (84450), and urea nitrogen (BUN) (84520). Blood specimen is obtained by venipuncture. See the specific codes for additional information about the listed tests.


When to use CPT 83036-83037

83036- Hemoglobin; Glycosylated

83037- Hemoglobin; Glycosylated (A1C) by device cleared by FDA for home use

These procedures are also known as HbA1C. In these tests a blood specimen is collected. Glycosylated hemoglobin levels reflect the average level of glucose in the blood over a three-month period. These methods can also include use of high-performance liquid chromatography and ion exchange chromatography (83036) or FDA approved home monitoring device (83037).

82306 Vitamin D; 25 Hydroxy, Includes Fraction(s), If Performed

This test may be requested as 25-OHD3, 25(OH) Calciferol, Vitamin D 25-Hydroxy, Vitamin D3 25-OH, or Calciferol 25-Hydroxy. Specimen is serum or plasma and method is high performance liquid chromatography (HPLC), competitive protein binding (CPB), or radioimmunoassay (RIA). This code includes fractions, if performed.

Use of code 84443 Thyroid Stimulating Hormone (TSH)

TSH is produced in the pituitary gland and stimulates the secretion of thyrotropin (T3) and thyroxine (T4); these secretory products monitor TSH. The specimen is serum, requiring special handling. Heel stick or umbilical cord sample is drawn from newborns and may be collected on a special paper. Methods may include radioimmunoassay (RIA), sandwich immunoradiometric assay (IRMA), fluorometric enzyme immunoassay with use of monoclonal antibodies, or microparticle enzyme immunoassay on IMx (MEIA). This test may be performed to determine thyroid function, to differentiate from various types of hypothyroidism (e.g., primary, and pituitary/hypothalamic), or to diagnose hyperthyroidism. The test may be ordered to evaluate therapy in patients receiving hypothyroid treatment, and to detect congenital hypothyroidism.

When to use CPT code 80050 General Health Panel

A general health panel includes the following tests: albumin (82040), total bilirubin (82247), calcium (82310), carbon dioxide (bicarbonate) (82374), chloride (82435), creatinine (82565), glucose (82947), alkaline phosphatase (84075), potassium (84132), total protein (84155), sodium (84295), alanine amino transferase (ALT) (SGPT) (84460), aspartate amino transferase (AST) (SGOT) (84450), urea nitrogen (BUN) (84520), and thyroid stimulating hormone (84443). In addition, this panel includes a hemogram with automated differential (85025 or 85027 and 85004) or hemogram (85027) with manual differential (85007 or 85009). Blood specimen is obtained by venipuncture. See specific codes for additional information about the listed tests.

80048 Basic Metabolic Panel, Calcium, Total

A basic metabolic panel with total calcium includes the following tests: total calcium (82310), carbon dioxide (82374), chloride (82435), creatinine (82565), glucose (82947), potassium (84132), sodium (84295), and urea nitrogen (BUN) (84520). The blood specimen is obtained by venipuncture. See the specific codes for additional information about the listed tests.

87491 Infectious Agent, Nucleic Acid (DNA/RNA); Chlamydia Trachomatis, Amplified Probe

This test may be requested as Chlamydia trachomatis or C. trachomatis by polymerase chain reaction. C. trachomatis is a frequently occurring sexually transmitted disease. It may cause nonspecific urethritis or pelvic inflammatory disease (PID), although it is frequently asymptomatic in women. Another serotype also causes conjunctivitis. The DNA is amplified using a technique such as polymerase chain reaction (PCR).

When to use CPT code 87086-87088

87086 Culture, Bacterial; Quantitative Colony Count, Urine

87087 Culture, Bacterial; w/Isolation & Presumptive ID Of Isolates, Urine

These codes report the performance of a urine bacterial culture with a calibrated inoculating device so that a colony count accurately correlates with the number of organisms in the urine. In 87088, isolation and presumptive identification of bacteria recovered from the sample is done by means of identifying colony morphology, subculturing organisms to selective media and the performance of a gram stain or other simple test to identify bacteria to the genus level. There are several automated systems that detect the presence of bacteria using colorimetric, radiometric, or spectrophotometric means. In 87086, quantified colony count numbers within the urine sample are measured.

Read also: Best coding tips for Follow up ICD 10 codes

Use of CPT code 87491 Infectious Agent, Nucleic Acid (DNA/RNA); Chlamydia Trachomatis, Amplified Probe

This test may be requested as Chlamydia trachomatis or C. trachomatis by polymerase chain reaction. C. trachomatis is a frequently occurring sexually transmitted disease. It may cause nonspecific urethritis or pelvic inflammatory disease (PID), although it is frequently asymptomatic in women. Another serotype also causes conjunctivitis. The DNA is amplified using a technique such as polymerase chain reaction (PCR).

82962 Glucose, Blood, Glucose Monitoring Device(s) Cleared By FDA Specifically For Home Use

This test is used to monitor disorders of carbohydrate metabolism. This test reports blood glucose monitoring by an FDA-approved device. While the code states that it is for home use, these devices may also be used in the physician office. Blood is obtained by finger stick. Method is enzymatic, electrochemical, or spectrophotometry by small portable device designed for home glucose testing.

82607 Cyanocobalamin (Vitamin B-12)

This test may be requested as antipernicious anemia factor, true cyanocobalamin, or Vitamin B12. It is essential for red blood cell maturation and for gastrointestinal and neurologic health. Decreased levels may be indicative of certain anemias. Method is chemiluminescence, competitive protein binding (CPB) radioassay, or radioimmunoassay (RIA).

Read also: Coding tips for Normal and Outcome of Delivery ICD 1o codes

When to use CPT code 84152-84154

84152 Prostate Specific Antigen (PSA); Complexed (Direct Measurement)

84153 Prostate Specific Antigen (PSA); Total

84154 Prostate Specific Antigen (PSA); Free

The specimen is serum. Methods may include radioimmunoassay (RIA) and monoclonal two-site immunoradiometric assay. These tests may be performed to determine the presence of cancer of the prostate, benign prostatic hypertrophy (BPH), prostatitis, post prostatectomy to detect residual cancer, and to monitor therapy. There are several forms of PSA present in serum. PSA may be complexed with the protease inhibitor alpha-1 antichymotrypsin (PSA-ACT). Complexed PSA is the most measurable form. PSA is also found in a free form. Free PSA is not complexed to a protease inhibitor. Higher levels of free PSA are more often associated with benign conditions of the prostate than with prostate cancer. Total PSA measures both complexed and free levels to provide a total amount present in the serum. A percentage of each form is sometimes calculated to distinguish benign from malignant conditions. Code 84152 reports complexed PSA; 84153 is for total serum PSA; 84154 is for free (not complexed) PSA.



APC Status Indicator Codes

APC Status Indicator Codes



A  



Services Paid under Fee Schedule or Payment System other than OPPS
B  Codes Not Recognized by OPPS when submitted on Outpatient Hospital Part B Bill Type (12x/13x)
C  Inpatient Procedures, not paid under OPPS
D  Discontinued Codes
E1  Non-Covered Service, not paid under OPPS
E2  Items and Services for which pricing information and claims data are not available
 FCorneal, CRNA and Hepatitis B
G  Pass-Through Drugs and Biologicals
H  Pass-Through Device Categories
J1  Hospital Part B services paid through a comprehensive APC
J2  Hospital Part B Services That May Be Paid Through a Comprehensive APC
K  Nonpass-Through Drugs and Nonimplantable Biologicals, Including Therapeutic Radiopharmaceuticals
L  Influenza Vaccine; Pneumococcal Pneumonia Vaccine
M  Items and Services Not Billable to the Fiscal Intermediary/MAC
N  Items and Services Packaged into APC Rates
P  Partial Hospitalization
Q1  STVX-Packaged Codes
Q2  T-Packaged Codes
Q3  Codes That May Be Paid Through a Composite APC
Q4  Conditionally packaged laboratory tests
R  Blood and Blood Products
S  Significant Procedure, Not Discounted When Multiple
T  Significant Procedure, Multiple Reduction Applies
U  Brachytherapy Sources
V  Clinic or Emergency Department Visit
X  Ancillary Services
Y  Non-Implantable Durable Medical Equipment

Sample Practice ICD 10 questions with Answers with codes

Sample Practice ICD 10 questions with Answers with codes
Postoperative fever R50.82

Postoperative esophagitis K20.9

Colostomy malfunction K94.03

Postleukotomy syndrome F07.0

Postoperative peritoneal adhesions K66.0

Postoperative blind loop syndrome K91.2



Cataract fragments in left eye following cataract surgery Complications H59.022

Headache due to lumbar puncture G97.1

Post-iridectomy plateau iris syndrome H21.82

Seroma of saphenous vein following cardiac bypass surgery I97.641

Postprocedural hypertension I97.3

35-year-old female patient presents to physician's office with complaints of flushing, sleeplessness, headache, and lack of concentration after having had uterine artery embolization for uterine leiomyoma a few months ago. Physician diagnoses patient with premature postsurgical
menopause. E89.41


Leakage of breast prosthesis T85.43xA

Intrauterine contraceptive device imbedded in uterine wall Imbedding T83.39xA

Erosion of skin by protruding pacemaker electrodes Complication T82.190A

Bone marrow transplant with rejection syndrome
Acute graft-versus-host disease Complication T86.01 D89.810

Displaced lens implant, right eye Complication T85.22xA

Complication of transplanted intestine
Malignant neoplasm of colon related to intestinal transplant T86.858 C80.2 C18.9

Broken right hip joint prosthesis after fall T84.010A

 A 60-year-old woman with type 2 diabetes had a right above-the-knee amputation two months ago due to severe diabetic circulatory problems in the limb. The stump had developed an abscess with
Staphylococcus aureus cultured. T87.43 B95.61 L02.415 E11.51

Kidney transplant failure with chronic kidney disease, stage IV T86.12 N18.4


Admitted for removal of internal fixation nail in right forearm that has extruded into surrounding tissue, causing severe pain Complication, orthopedic T84.192A

Admitted for closure of colostomy Z43.3

Admitted for adjustment of breast prosthesis Z44.30

Admitted for removal of displaced breast prosthesis Complication, surgical, internal T85.42xA





Infected injection site, left buttock or Complications T80.29xA

Sloughing of skin graft due to rejection of pedicle graft to right arm T86.820

Headache due to lumbar puncture G97.1

Postoperative cardiac arrest occurring in operating room during closure of abdomen, with successful resuscitation I97.711

Persistent vomiting following gastrointestinal surgery K91.0

Air embolism resulting from intravenous infusion T80.0xxA

Thrombophlebitis of antecubital vein of the upper arm resulting from intravenous infusion Postoperative T80.1xxA I80.8

Hypovolemic shock due to surgery this morning Postoperative T81.19xA

Persistent postoperative fistula T81.83xA

Cardiac insufficiency resulting from mitral valve prosthesis, in place for three years I97.110

Perforation of coronary artery by catheter during cardiac catheterization Complication I97.51

Displacement of cardiac pacemaker electrode Complication, mechanical T82.120A

Phantom limb with pain following surgical amputation G54.6

Neuroma of stump following surgical amputation of left leg T87.34

Methicillin-susceptible Staphylococcus aureus infection of transplanted kidney Complication, transplant, organ T86.13 B95.61

A patient with leukemia is admitted to the hospital after noting feelings of palpitations and shortness of breath. The patient has an infusion catheter in place for the administration of chemotherapy. A chest X-ray shows that the tip of the infusion catheter had broken off and traveled to the pulmonary artery. Complication, vascular device T82.514A C95.90

ASPIRIN/DIPYRIDAMOLE

ASPIRIN/DIPYRIDAMOLE

Dipyridamole is an antiplatelet agent chemically described as 2,2',2'',2'''-[(4,8-Dipiperidinopyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]-tetraethanol. 

Dipyridamole is an odorless yellow crystalline substance, having a bitter taste. It is soluble in dilute acids, methanol and chloroform, and is practically insoluble in water.

The antiplatelet agent aspirin (acetylsalicylic acid) is chemically known as benzoic acid, 2- (acetyloxy). Aspirin is an odorless white needle-like crystalline or powdery substance. When exposed to moisture, aspirin hydrolyzes into salicylic and acetic acids, and gives off a vinegary odor. It is highly lipid soluble and slightly soluble in water.


Requires Prescription: Yes
Generic Name
  • Aspirin/Dipyridamole
Brand Names
  • Aggrenox
Therapeutic Class
  • Platelet Aggregation Inhibitor, Phosphodiesterase Inhibitor/Salicylate, Aspirin Combination
FDA-Label Indications
  • Thromboembolic stroke, Recurrent; Prophylaxis: Adult
Common Effects
  • Gastrointestinal: Abdominal pain (17.5% ), Diarrhea (12.7% ), Indigestion (18.4% )
  • Hematologic: Blood coagulation disorder with prolonged bleeding time, Hemorrhage
  • Musculoskeletal: Arthralgia (5.5% )
  • Neurologic: Headache (39.2% )
Serious Effects
  • Dermatologic: Stevens-Johnson syndrome
  • Gastrointestinal: Gastrointestinal hemorrhage (1.2% ), Gastrointestinal perforation (less than 1% ), Gastrointestinal ulcer (less than 1% )
  • Neurologic: Intracranial hemorrhage (0.6% )
  • Other: Angioedema, Reye's syndrome
Administration
  • Oral: take with or without food
  • Oral: swallow whole; do not chew
  • Instillation, gastrostomy tube: open the fixed-dose dipyridamole/aspirin capsule and separate the aspirin tablet and the dipyridamole pellets; crush the aspirin and instill in 10 mL of water through the gastrostomy tube (G-tube); suspend the dipyridamole extended-release pellets in 10 mL of water and instill through the G-tube; immediately flush the G-tube with 20 mL of water; inspect the external portion of the G-tube for residual drug and flush with additional volume of water if necessary
How Supplied - Trade
  • Aggrenox: Oral Capsule, Extended Release: (Aspirin - Dipyridamole) 25 MG-200 MG
How Supplied - Generic
  • Oral Capsule, Extended Release: (Aspirin - Dipyridamole) 25 MG-200 MG
Adult Dose
  • Important Note: Beers Criteria: Use caution or avoid use as potentially inappropriate in older adults .
  • Hemodialysis - Thrombosis; Prophylaxis: Aspirin 25 mg/extended-release dipyridamole 200 mg orally twice daily (off-label dosage)
  • Thromboembolic stroke, Recurrent; Prophylaxis: 1 capsule (aspirin 25 mg/extended-release dipyridamole 200 mg) orally twice a day in the morning and evening
Pediatric Dose
  • Important Note: Beers Criteria: Use caution or avoid use as potentially inappropriate in older adults .
  • General Dosage Information: safety and effectiveness in pediatric patients have not been studied; due to the aspirin component, this product is not recommended in the pediatric population
Pharmacokinetics
  • Aspirin, Tmax, oral: 0.63 hour after a daily dose of 25 mg twice a day, and 1 hour for salicylic acid
  • Dipyridamole, Tmax, oral: 2 hours after a daily dose of 200 mg twice a day
  • Aspirin, bioavailability, oral: 50 to 75%
  • Dipyridamole extended-release, bioavailability, oral, : 37% to 66%
  • Effects of food: not clinically significant; fixed combination can be given with or without food
Copyright © 2017 by Thomson Healthcare Inc. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.

ASPIRIN Brand name and dosage

ASPIRIN Brand name and dosage

Aspirin is used to relieve pain and reduce fever in patients. It belongs to the group of medicines known as salicylates and acts on the immune system to reduce inflammation. It is also known as an anti-inflammatory analgesic.
Aspirin has analgesic, antipyretic, anti-inflammatory, and antirheumatic effects; its analgesic and anti-inflammatory effects may be mediated through inhibition of prostaglandin synthetase enzyme complex. 


Requires Prescription: Available in both over the counter and prescription formulations
Generic Name
  • Aspirin
Brand Names
  • Ecotrin
  • Bayer
  • Ascriptin
  • Aspergum
  • Aspirtab
  • Easprin
  • Ecpirin
  • Entercote
Therapeutic Class
  • Analgesic
  • NSAID
  • Platelet Aggregation Inhibitor
  • Salicylate, Aspirin
FDA-Label Indications
  • Carotid endarterectomy: Adult
  • Cerebrovascular accident: Adult
  • Cerebrovascular accident, Secondary; Prophylaxis: Adult
  • Coronary artery bypass graft: Adult
  • Disorder of joint of spine: Adult
  • Disorder of joint of spine: Pediatric
  • Fever: Adult
  • Fever: Pediatric: yes (12 years or older)
  • Generalized aches and pains: Adult
  • Generalized aches and pains: Pediatric: yes (12 years or older)
  • Headache: Adult
  • Headache: Pediatric: yes (12 years or older)
  • Migraine: Adult
  • Myocardial infarction: Adult
  • Myocardial infarction, In patients with chronic coronary artery disease; Prophylaxis: Adult
  • Myocardial infarction, Primary; Prophylaxis: Adult
  • Osteoarthritis: Adult
  • Pain: Adult
  • Pain: Pediatric
  • Percutaneous coronary intervention: Adult
  • Rheumatoid arthritis: Adult
  • Rheumatoid arthritis: Pediatric
  • Stable angina, chronic: Adult
  • Systemic lupus erythematosus, Arthritis and Pleurisy: Adult
  • Transient ischemic attack; Treatment and Prophylaxis: Adult
  • Unstable angina: Adult
Serious Effects
  • Gastrointestinal: Gastrointestinal ulcer
  • Hematologic: Hemorrhage
  • Ophthalmic: Exudative age-related macular degeneration
  • Otic: Tinnitus
  • Respiratory: Bronchospasm
  • Other: Angioedema, Reye's syndrome
Administration
  • Oral: Take with a full glass of water (8 ounces or more)
  • Oral: (Extended-release tablets) Do not break Zorprin(R) tablets; swallow intact
  • Oral: (Extended-release capsules) Do not cut, crush, or chew Durlaza(R) capsules; swallow whole
  • Oral: (Extended-release capsules) Take with a full glass of water and take at the same time each day
  • Oral: (Extended-release capsules) Do not take 2 hours before or 1 hour after consuming alcohol
How Supplied - Trade
  • Adult Low Dose Aspirin: Oral Tablet, Chewable: 81 MG
  • Aspergum: Oral Gum: 227 MG
  • Aspirin Adult Low Dose: Oral Tablet, Enteric Coated: 81 MG
  • Aspirin Low Dose: Oral Tablet, Enteric Coated: 81 MG
  • Aspirin: Oral Tablet, Chewable: 81 MG
  • Aspirin: Oral Tablet, Enteric Coated: 81 MG
  • Aspir Low: Oral Tablet, Enteric Coated: 81 MG
  • Bayer Aspirin Children's: Oral Tablet, Chewable: 81 MG
  • Bayer Aspirin Regimen: Oral Tablet, Enteric Coated: 81 MG
  • Bayer Extra Strength: Oral Tablet: 500 MG
  • Bayer Genuine Aspirin: Oral Tablet: 325 MG
  • Bayer Low Dose: Oral Tablet, Enteric Coated: 81 MG
  • Bufferin: Oral Tablet: 500 MG
  • Children's Aspirin: Oral Tablet, Chewable: 81 MG
  • Durlaza: Oral Capsule, Extended Release, 24 HR: 162.5 MG
  • Ecotrin: Oral Tablet, Enteric Coated: 325 MG, 500 MG
  • Ecpirin: Oral Tablet, Enteric Coated: 325 MG
  • Enteric Aspirin: Oral Tablet, Enteric Coated: 325 MG
  • Equate Aspirin: Oral Tablet, Enteric Coated: 81 MG, 325 MG
  • Equate Chewable Aspirin: Oral Tablet, Chewable: 81 MG
  • Genuine Aspirin: Oral Tablet: 325 MG
  • Good Neighbor Pharmacy Aspirin: Oral Tablet: 325 MG
  • Good Neighbor Pharmacy Aspirin: Oral Tablet, Enteric Coated: 81 MG
  • Good Sense Aspirin: Oral Tablet: 325 MG
  • Good Sense Aspirin: Oral Tablet, Chewable: 81 MG
  • Good Sense Aspirin: Oral Tablet, Enteric Coated: 81 MG, 325 MG
  • Halfprin: Oral Tablet, Enteric Coated: 162 MG
  • Health Mart Aspirin: Oral Tablet, Chewable: 81 MG
  • Health Mart Low Dose Aspirin: Oral Tablet, Enteric Coated: 81 MG
  • Leader Aspirin: Oral Tablet, Chewable: 81 MG
  • Leader Aspirin: Oral Tablet, Enteric Coated: 81 MG, 325 MG
  • Medi-First Aspirin: Oral Tablet: 325 MG
  • Miniprin: Oral Tablet, Enteric Coated: 81 MG
  • Pain Relief Aspirin: Oral Tablet: 325 MG
  • Pain Relief Aspirin: Oral Tablet, Enteric Coated: 325 MG
  • Quality Choice Aspirin: Oral Tablet: 325 MG
  • Quality Choice Aspirin: Oral Tablet, Enteric Coated: 81 MG
  • Quality Choice Chewable Aspirin: Oral Tablet, Chewable: 81 MG
  • Quality Choice Enteric Aspirin: Oral Tablet, Enteric Coated: 325 MG
  • Quality Choice Lo-Dose Aspirin: Oral Tablet, Enteric Coated: 81 MG
  • Sunmark Aspirin: Oral Tablet, Chewable: 81 MG
  • Sunmark Aspirin: Oral Tablet, Enteric Coated: 81 MG
  • Sunmark Enteric Coated Aspirin: Oral Tablet, Enteric Coated: 325 MG
  • TopCare Aspirin: Oral Tablet, Chewable: 81 MG
  • TopCare Aspirin: Oral Tablet, Enteric Coated: 81 MG, 325 MG
  • Up & Up Aspirin Low Dose: Oral Tablet, Enteric Coated: 81 MG
  • Up & Up Aspirin: Oral Tablet: 325 MG
  • Up & Up Aspirin: Oral Tablet, Chewable: 81 MG
How Supplied - Generic
  • Oral Tablet: 325 MG
  • Oral Tablet, Chewable: 81 MG
  • Oral Tablet, Enteric Coated: 81 MG, 325 MG, 500 MG, 650 MG
  • Rectal Suppository: 300 MG, 600 MG
Adult Dose
  • Important Note: Beers Criteria: Use caution or avoid use as potentially inappropriate in older adults .
  • Atrial fibrillation - Thromboembolic disorder; Prophylaxis: 75 to 325 mg ORALLY daily
  • Carotid artery stenosis: 75 to 100 mg/day ORALLY
  • Carotid endarterectomy: 75 to 100 mg ORALLY once a day
  • Cerebrovascular accident: 160 to 325 mg ORALLY within 48 hours of event, followed by secondary prophylaxis with 75 to 100 mg daily
  • Cerebrovascular accident, Secondary; Prophylaxis: (Extended-release capsule) 162.5 mg orally once daily (FDA dosage)
  • Cerebrovascular accident, Secondary; Prophylaxis: 50 to 325 mg orally per day (guideline dosage)
  • Colorectal cancer; Prophylaxis: Dosage (50 to 59 years with a 10% or greater 10-year cardiovascular disease risk): 81 mg orally daily (guideline dosage)
  • Colorectal cancer; Prophylaxis: Dosage (60 to 69 years with a 10% or greater 10-year CVD risk): 81 mg orally daily based on assessment the individual patient (guideline dosage) .
  • Coronary artery bypass graft: 75 to 100 mg ORALLY per day started postoperatively and continued long-term
  • Disorder of cardiovascular system, Primary Prophylaxis: Dosage (50 to 59 years with a 10% or greater 10-year cardiovascular disease risk): 81 mg orally daily (guideline dosage)
  • Disorder of cardiovascular system, Primary Prophylaxis: Dosage (60 to 69 years with a 10% or greater 10-year CVD risk): 81 mg orally daily based on assessment the individual patient (guideline dosage) .
  • Disorder of cardiovascular system, Primary Prophylaxis: (Adults with diabetes) 75 to 162 mg orally daily (guideline dosage)
  • Disorder of cardiovascular system, Secondary Prophylaxis: 81 mg orally daily (range, 75 to 100 mg/day), continued indefinitely in almost all patients (guideline dosage)
  • Disorder of cardiovascular system, Secondary Prophylaxis: Dual antiplatelet therapy (acute coronary syndrome managed with medical therapy alone), clopidogrel OR ticagrelor for at least 12 months; may continue beyond 12 months in select patients (guideline dosage)
  • Disorder of cardiovascular system, Secondary Prophylaxis: Dual antiplatelet therapy (ST-elevation myocardial infarction managed with fibrinolytics), clopidogrel for a minimum of 14 days and ideally at least 12 months; may continue beyond 12 months in select patients (guideline dosage)
  • Disorder of cardiovascular system, Secondary Prophylaxis: Dual antiplatelet therapy (percutaneous coronary intervention with bare metal or newer generation drug-eluting stent (DES)), clopidogrel OR ticagrelor OR prasugrel for at least 12 months; may continue beyond 12 months in select patients; may consider discontinuation after 6 months in patient with DES and high bleeding risk (guideline dosage)
  • Disorder of cardiovascular system, Secondary Prophylaxis: Dual antiplatelet therapy (undergoing CABG following acute coronary syndrome), resume P2Y12 inhibitor after CABG to complete recommended duration of therapy (guideline dosage)
  • Disorder of joint of spine: up to 4 g ORALLY per day in divided doses
  • Fever: 325 to 650 mg ORALLY every 4 to 6 hours as needed; maximum 4 g in 24 hours
  • Flushing, Niacin Induced: 325 mg or 650 mg orally 30 minutes prior to niacin therapy (off-label dosage)
  • Generalized aches and pains: 325 to 650 mg ORALLY every 4 hours; MAX: 3.9 g/24 hours
  • Headache: 500 mg to 1000 mg ORALLY every 4 to 6 hours; MAX: 4 g/24 hours
  • Headache: (12 years or older) 500 mg to 1000 mg ORALLY every 4 to 6 hours; MAX: 4 g/24 hours
  • Migraine: 1000 mg ORALLY one time; MAX: 1000 mg/24 hours
  • Myocardial infarction: Initial, chew 162 to 325 mg orally immediately at symptom onset (guideline dosage)
  • Myocardial infarction, In patients with chronic coronary artery disease; Prophylaxis: (Extended-release capsules) 162.5 mg orally daily
  • Myocardial infarction, Primary; Prophylaxis: 75 to 100 mg orally daily (guideline dosage)
  • Myocardial infarction, Secondary; Prophylaxis: 81 mg orally daily (range, 75 to 100 mg/day), continued indefinitely in almost all patients (guideline dosage)
  • Myocardial infarction, Secondary; Prophylaxis: Dual antiplatelet therapy (managed with medical therapy alone), clopidogrel OR ticagrelor for at least 12 months; may continue beyond 12 months in select patients (guideline dosage)
  • Myocardial infarction, Secondary; Prophylaxis: Dual antiplatelet therapy (ST-elevation myocardial infarction managed with fibrinolytics), clopidogrel for a minimum of 14 days and ideally at least 12 months; may continue beyond 12 months in select patients (guideline dosage)
  • Myocardial infarction, Secondary; Prophylaxis: Dual antiplatelet therapy (percutaneous coronary intervention with bare metal or newer generation drug-eluting stent (DES)), clopidogrel OR ticagrelor OR prasugrel for at least 12 months; may continue beyond 12 months in select patients; may consider discontinuation after 6 months in patient with DES and high bleeding risk (guideline dosage)
  • Myocardial infarction, Secondary; Prophylaxis: Dual antiplatelet therapy (undergoing CABG), resume P2Y12 inhibitor after CABG to complete 12 months of therapy following acute coronary syndrome (guideline dosage)
  • Osteoarthritis: up to 3 g ORALLY a day in divided doses
  • Pain: 325 to 650 mg ORALLY every 4 hours; MAX: 3.9 g/24 hours
  • Percutaneous coronary intervention: 81 mg orally daily (range, 75 to 100 mg/day), continued indefinitely in almost all patients (guideline dosage)
  • Percutaneous coronary intervention: Dual antiplatelet therapy (acute coronary syndrome and bare metal or newer generation drug-eluting stent (DES)), clopidogrel OR ticagrelor OR prasugrel for at least 12 months; may continue beyond 12 months in select patients; may consider discontinuation after 6 months in patient with DES and high bleeding risk (guideline dosage)
  • Percutaneous coronary intervention: Dual antiplatelet therapy (stable ischemic heart disease with bare-metal stent), clopidogrel for at least 1 month; may continue beyond 1 month in select patients (guideline dosage)
  • Percutaneous coronary intervention: Dual antiplatelet therapy (stable ischemic heart disease with newer generation drug-eluting stent), clopidogrel for at least 6 months; may continue beyond 6 months in select patients; may consider discontinuation of clopidogrel after 3 months in patient with high bleeding risk (guideline dosage)
  • Peripheral arterial occlusive disease: 75 to 100 mg ORALLY per day
  • Peripheral arterial occlusive disease - Thrombosis; Prophylaxis: 75 to 100 mg orally per day (Guideline dosage)
  • Prosthetic replacement of heart valve - Thromboembolic disorder; Prophylaxis: 50 to 100 mg ORALLY per day
  • Prosthetic replacement of heart valve - Thromboembolic disorder; Prophylaxis: (pregnant women at high risk for thromboembolism) 75 to 100 mg ORALLY daily
  • Rheumatoid arthritis: initial, 3 g ORALLY a day (divide every 4 to 6 hours), increase as needed for anti-inflammatory efficacy with target plasma salicylate levels of 150 to 300 mcg/mL
  • Stable angina, chronic: 75 to 325 mg ORALLY once a day
  • Systemic lupus erythematosus, Arthritis and Pleurisy: initial, 3 g a day ORALLY in divided doses, increase as needed for anti-inflammatory efficacy with target plasma salicylate levels of 150 to 300 mcg/mL
  • Transient ischemic attack; Treatment and Prophylaxis: initial, 160 to 325 mg ORALLY within 48 hours of event
  • Transient ischemic attack; Treatment and Prophylaxis: (secondary prophylaxis) 75 to 100 mg ORALLY daily
  • Unstable angina: 75 to 325 mg ORALLY once a day
Pediatric Dose
  • Important Note: Beers Criteria: Use caution or avoid use as potentially inappropriate in older adults .
  • Cerebrovascular accident: (acute arterial ischemic stroke, with or without thrombophilia) 1 to 5 mg/kg/day ORALLY initially until dissection and cardioembolic causes are excluded; if excluded, continue aspirin prophylaxis for at least 2 years
  • Fever: 12 years or older, 325 to 650 mg ORALLY every 4 to 6 hours as needed; maximum 4 g in 24 hours
  • Fever: 40 to 60 mg/kg/day (divide every 4 to 6 hours) ORALLY, MAX 4 g in 24 hours
  • Generalized aches and pains: 12 years or older, 325 to 650 mg ORALLY every 4 hours; MAX: 3.9 g/24 hours
  • Kawasaki disease: (AHA and AAP recommendations) high-dose (acute phase), 80 to 100 mg/kg/day (divided every 6 hours) ORALLY; continue therapy until afebrile for 48 to 72 hours, OR until day 14 of illness and afebrile for at least 48 hours; then low-dose, 3 to 5 mg/kg/day until no evidence of coronary changes, usually 6 to 8 weeks after onset of illness; continue low-dose aspirin indefinitely for patients with underlying coronary abnormalities
  • Kawasaki disease: (ACCP recommendations) short-term phase, 80 to 100 mg/kg/day ORALLY for up to 14 days, followed by 1 to 5 mg/kg/day for 6 to 8 weeks
  • Pain: 12 years or older, 325 to 650 mg ORALLY every 4 hours; MAX: 3.9 g/24 hours
  • Pain: 40 to 60 mg/kg/day (divide every 4 to 6 hours) ORALLY, MAX 4 g in 24 hours
  • Rheumatoid arthritis: (juvenile) initial 90 to 130 mg/kg/day (divide every 4 to 6 hours) ORALLY, increase as needed for anti-inflammatory efficacy with target plasma salicylate levels of 150 to 300 mcg/mL
Pharmacokinetics
  • Tmax, Oral, immediate-release: 1 hour
  • Tmax, Oral, extended-release: 2 hours
  • Tmax, Oral, buffered tablet: 20 minutes .
  • Tmax, Oral, effervescent solution: 15 minutes .
  • Bioavailability, Oral, immediate release: Well and completely absorbed
  • Bioavailability, Oral, enteric coated: Erratically absorbed
  • Effect of food: Delayed absorption with single dose; Tmax increased from 1.74 to 2.65 hours
Copyright © 2017 by Thomson Healthcare Inc. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.